News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Insmed Incorporated Announces Promising Results From IPLEX Phase II Myotonic Muscular Dystrophy Clinical Study
May 3, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
RICHMOND, Va.--(BUSINESS WIRE)--Insmed Inc. (Nasdaq:INSM) today announced positive results from a Phase II investigator-sponsored study of the company’s drug, IPLEXTM, in patients with myotonic muscular dystrophy (DM1).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Insmed Incorporated
MORE ON THIS TOPIC
IN PARTNERSHIP WITH ECLIPSEBIO
The mRNA Revolution You Haven’t Heard About: From Cystic Fibrosis to Personalized Cancer Vaccines
July 10, 2025
·
1 min read
·
Lori Ellis
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
July 10, 2025
·
1 min read
·
Dan Samorodnitsky
Rare diseases
Ultragenyx, Mereo Plummet After Late-Stage Trial for Rare Genetic Disorder Appears To Fall Short
July 10, 2025
·
2 min read
·
Tristan Manalac
Startups
Longevity Biotechs Strive for Better Aging—Not Just Life Extension
July 9, 2025
·
3 min read
·
Tristan Manalac
